One To Watch

Newron Pharmaceuticals

A CNS-focused biopharmaceutical company with a track record of advancing assets through late-stage development and partnering for commercialization.

Headquarters and Global Presence

Newron Pharmaceuticals is headquartered in Bresso (near Milan), Italy, with a U.S. subsidiary in Morristown, New Jersey. The company is publicly listed on the SIX Swiss Exchange (NWRN) and is also traded in Germany (including XETRA under NP5).

Founding and History

Newron is a CNS-focused biopharmaceutical company with a track record of advancing assets through late-stage development and partnering for commercialization. Its first marketed product, Xadago (safinamide) for Parkinson’s disease, was approved in the EU in 2015 and in the U.S. in 2017. Newron’s current strategic center of gravity is evenamide, a late-stage asset being developed for schizophrenia.

Therapy Areas and Focus

Newron focuses on disorders of the central and peripheral nervous system. Current priorities are:

Schizophrenia, including treatment-resistant schizophrenia and patients with inadequate response to standard antipsychotics
Parkinson’s disease, through partnered commercialization of safinamide
The company has also referenced interest in selective in-licensing to broaden its CNS portfolio.

Technology Platforms and Modalities

Newron’s pipeline is small-molecule–led.

Evenamide (lead development asset)

Mechanism: a glutamate-modulating approach, described by the company as linked to voltage-gated sodium channel blockade and reduction of excessive glutamate release
Development focus: add-on therapy to existing antipsychotics for schizophrenia populations with persistent symptoms
Stage: pivotal Phase III program (ENIGMA-TRS)

Xadago (safinamide; partnered, marketed)

Indication: adjunct therapy in Parkinson’s disease
Status: approved and commercialized via partners in multiple geographies

Key Personnel

Newron’s senior management team includes:

Stefan Weber, Executive Director and CEO
Ravi Anand, MD, Chief Medical Officer
Roberto Galli, Chief Financial Officer
Dennis Dionne, VP Commercial Affairs
Filippo Moriggia, VP Operations
Laura Faravelli, VP Business Development

Strategic Partnerships

Newron uses territorial licensing to fund development and extend reach:

Evenamide: development and commercialization agreements with EA Pharma (an Eisai subsidiary) for Japan and other Asian territories, and with Myung In Pharm for South Korea
Xadago (safinamide): commercialized through partners including Zambon (notably Europe/other markets), Meiji Seika (Japan) and US WorldMeds (U.S.)

FAQ Section

Newron develops small-molecule therapies for CNS and peripheral nervous system disorders, with a current emphasis on neuropsychiatry. The company’s lead program, evenamide, is positioned as a first-in-class glutamate modulator intended for add-on use in schizophrenia.

Newron’s core focus is schizophrenia (including treatment-resistant and poorly responding populations) and Parkinson’s disease (through the marketed safinamide franchise partnered for commercialization).

The lead pipeline program is evenamide in schizophrenia, being advanced in a pivotal Phase III program (ENIGMA-TRS). The company’s marketed product is Xadago (safinamide) for Parkinson’s disease, commercialized by partners.

January 7, 2026: partner EA Pharma announced initiation of its Phase III clinical trial with evenamide in Japan
2026: the company has highlighted expansion of its intellectual property estate, including a new EU composition-of-matter patent relating to evenamide
May 2025: regulatory approval to proceed with the pivotal Phase III ENIGMA-TRS program for evenamide in treatment-resistant schizophrenia and related high-need schizophrenia populations

Newron’s current Phase III strategy for evenamide follows prior studies reporting sustained symptom improvements when evenamide was used as add-on therapy in difficult-to-treat schizophrenia populations. These earlier datasets underpin the ENIGMA-TRS pivotal program design.

Near-term milestones are execution-driven: ongoing conduct of the ENIGMA-TRS Phase III program (including study start-up and enrollment progress across geographies) and partner-led Phase III execution in Japan. Additional milestones typically include interim operational updates and, later, topline readouts from Phase III studies.

Newron is led by a long-tenured CNS development team with clinical, regulatory, finance, and commercial experience. Its operating model combines internal clinical development of key assets with territorial licensing to partners for regional development and commercialization.

Want to Update your Company's Profile?